^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Lung Non-Squamous Non-Small Cell Cancer
    Drug:Alymsys (bevacizumab-maly) (VEGF-A inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    FDA
    Published date:
    04/13/2022
    Excerpt:
    Alymsys is a vascular endothelial growth factor inhibitor indicated for the treatment of...Unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel for first-line treatment.
    Secondary therapy:
    carboplatin + paclitaxel